WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Vibrant festival highlights cultural charm of various Chinese ethnic groupsKevin Bacon returns to 'Footloose' high schoolAttractive female faces make men behave more honestly, study suggestsIran's supreme leader acknowledges it hit little in Israel attackMandisa, GrammyHands, Face, Prays! FootballKenyan president confirms military chief's death in plane crashChina's Dongfeng NEV brand Voyah makes debut in ItalyHoroscope today: Daily guide to what the stars have in store for YOUFormer Duke guard Jeremy Roach indicates he will play a final college season at Baylor